SEC Form 4 · accession 0001104659-17-029416
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara Y Chan
Officer — See Remarks
Period of report
May 1, 2017
Accepted (ET)
May 3, 2017 · 4:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $9.93 | May 1, 2017 | A | 20,000 | A | — | May 1, 2027 | Common Shares | 20,000 | 20,000 | D |
Explanation of responses
- F1Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date.
- F2Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one of its affiliates, 6,666 common shares underlying this stock option award will vest on May 1, 2018, 6,667 common shares underlying this stock option award will vest on May 1, 2019 and 6,667 common shares underlying this stock option award will vest on May 1, 2020.
Remarks
President and Chief Accounting Officer of Aegerion Pharmaceuticals, Inc.